Arthritis Drug Patents Expiring 2024 – 2028
The arthritis treatment industry is characterized by its intense competitiveness, driving companies to invest significantly in research and development to secure leading arthritis drug patents. Consequently, the expiration of patents for this disease creates significant opportunities for companies specializing in generic medications.
A notable example of the market dynamics in this industry is the case of Humira, a drug developed by AbbVie which became the most lucrative pharmaceutical product in the arthritis treatment sector. AbbVie faced criticism for employing strategies to extend its patent exclusivity and delay the entry of generic and biosimilar competitors into the market. However, in 2016, with the patent expiration, the market started seeing a surge in biosimilar and generic drug competitors, including Amgen’s Amjevita, leading to a decrease in arthritis treatment costs.
Therefore, the significance of tracking patent expirations in this field cannot be overstated. Identifying patents set to expire enables you to enhance and diversify your generic drug portfolios strategically. This approach is crucial for reducing reliance on a single product and mitigating risk through portfolio diversification.
Our comprehensive list provides essential insights, including the active ingredients, applicants, and administration routes of these expiring patents.
This information is vital for generic drug manufacturers planning to enter the arthritis treatment market strategically. For example, knowing the specific route of administration used in the original patented drug is key for formulating generic versions that maintain therapeutic equivalence.
While this article highlights key details, you can obtain the complete PDF version of “Arthritis Drug Patents Expiring in 2024-2028” by simply filling out the form below. Don’t miss this opportunity to stay ahead in the dynamic pharmaceutical landscape.
ARTHRITIS DRUG PATENTS EXPIRING FROM 2024 TO 2028
Colcrys
Colchicine
Applicant:
Takeda Pharmaceuticals USA Inc.
| Patents | Expiration Date | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ingredients: Colchicine
Route: Tablet;Oral
Duexis
Famotidine; Ibuprofen
Applicant:
Horizon Medicines LLC.
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Famotidine; Ibuprofen
Route: Tablet;Oral
Duzallo
Allopurinol; Lesinurad
Applicant:
Ironwood Pharmaceuticals Inc.
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Allopurinol; Lesinurad
Route: Tablet;Oral
Pennsaid
Diclofenac Sodium
Applicant:
Horizon Therapeutics Ireland Dac
| Patents | Expiration Date |
|---|---|
| US8252838 | 21-Apr-2028 |
Ingredients: Diclofenac Sodium
Route: Solution;Topical
Zurampic
Lesinurad
Applicant:
Ironwood Pharmaceuticals Inc.
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Lesinurad
Route: Tablet;Oral
Conclusion
As a drug patent expires, it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies.
However, there still lie legal and technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version.
One recent example is the legal dispute involving AbbVie and its arthritis drug, Rinvoq. In November 2023, AbbVie sued several generic drug manufacturers, including Sandoz, Hetero Labs, Aurobindo Pharma, Intas Pharmaceuticals, and Sun Pharmaceutical, for trying to release generic versions of Rinvoq. AbbVie claimed these companies were attempting to bypass Rinvoq’s patent thicket, similar to Humira’s protection strategy. This case demonstrates that even after a drug’s patent expires, the original patent holder may still take steps to defend its product, highlighting the need for detailed research and analysis in developing a generic drug.
Therefore, if proper research and threat analysis were conducted, developing a generic version of the arthritis drug wouldn’t be as daunting.
How to go about it?
Well, let’s start with getting in touch by filling out the form below, and we’ll get back to you in no time.
Authored by: Annie Sharma, Editorial Team
Insights by: Nikhil Kaushal, Product Development Team
